51 results about "Morphine" patented technology

The invention provides a nucleic acid aptamer for specific recognition of morphine and application of the nucleic acid aptamer, and belongs to the technical field of biosensing and detection. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 1. The screening method is based on a Capture-SELEX technology and comprises the key steps that streptavidin magnetic beads are used for fixing an ssDNA library, estradiol, deabietic acid and totarol are introduced to serve as reverse screening substances so as to remove non-specific sequences, and finally the high-specificity aptamer is obtained through high-throughput sequencing and affinity determination. The dissociation constant of the aptamer and morphine is 127.31 nM, and the aptamer shows high affinity and high specificity. The invention further relates to application of the aptamer in preparation of a sensor and a kit for detecting morphine, and a new technical means is provided for rapid detection of morphine.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The application provides a method for detecting psychotropic drugs in environmental sludge based on acid pretreatment, which comprises the following steps: S1: obtaining a sludge sample to be detected, performing pressurized fluid extraction on the sludge sample to be detected after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an eluate, and redissolving the eluate to obtain a solution to be detected, wherein the pressurized fluid extraction is performed under the condition of 5 ‰ formic acid water without heating; and S2: performing liquid chromatography mass spectrometry on the solution to be detected to obtain a mass spectrum, wherein the psychotropic drug is one of eptazocine, codeine, AMP, MAMP, MDA, monoacetylmorphine, MDMA, PMMA, fentanyl, norfentanyl, ketamine, norfentanyl, benzoyl eptazocine, cocaine and tramadol, and the method realizes detection of multiple psychotropic drugs in environmental sludge.

The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantageous properties as a therapeutic, including a favorable tolerability, an improved side effect profile, particularly a reduced occurrence of skin nodule formation and panniculitis when administered subcutaneously, as well as pharmacokinetic and metabolic properties rendering it particularly well-suited as an apomorphine prodrug. The invention further relates to the compound of formula (I) for use as a medicament, particularly for use in the treatment of Parkinson's disease.

The present invention discloses a method for preparing water-soluble quantum dots. The preparation method uses a surfactant solution to coat oil-soluble quantum dots, retaining the fluorescence of the oil-soluble quantum dots, and uses water-soluble polymer ligands (polyvinyl alcohol and polyvinyl pyrrolidone) to complete functional modification, thereby solving the problems of easy quenching of quantum dot fluorescence, inability of nanoparticles to stably agglomerate, and prone to nonspecific adsorption, resulting in low detection sensitivity. When the water-soluble quantum dots prepared by the preparation method of the present invention are used for biomarker detection, they can be directly dissolved in water, and the fluorescent group is stable, can stably agglomerate and specifically adsorb biological targets; therefore, the immunochromatographic test strips prepared using the water-soluble quantum dots can simply and stably adsorb drug antibodies, thereby improving detection sensitivity, with the detection sensitivity for morphine reaching 0.1 ng / mL.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The invention relates to a medicine with drug rehabilitation and relapse prevention effects as well as a preparation method and application thereof, and belongs to the field of medicines. The medicine comprises rotundine and salts and is prepared through a chemical synthesis method, and experiments prove that the medicine preparation has the effects of treating opioid substances including heroin, morphine, dolantin, methadone and the like as well as other psychoactive substances, such as opioid and the like. Independent or addiction formed by cocaine, amphetamine stimulants, wine, smoke, cannabis sativa, sedative and hypnotic drugs and the like has the effects of detoxifying, relieving symptoms, inhibiting psychological craving and reducing relapse rate.

The invention relates to the technical field of medicines, and discloses a novel light cuspidine type diterpenoid alkaloid compound and application of the novel light cuspidine type diterpenoid alkaloid compound. According to the present invention, the novel C20 selaginine type diterpenoid alkaloids such as the Carmaloidline C, the Carmaloidline D and the Aconialoidline C, which are provided by the present invention, all have significant analgesic effects; wherein the analgesic activity of the Carmaloidline C is the strongest, is superior to that of the positive drug morphine and is obviously superior to that of the positive drug ibuprofen, and the analgesic activity of the Carmaloidline D and the analgesic activity of the Aponiloidline C are superior to that of the positive drug ibuprofen. The medicines can be used for developing analgesic medicines for various acute or chronic pains.

The invention relates to the technical field of drug detection, in particular to an environment drug detection and collection reagent and a use method thereof.The environment drug detection and collection reagent comprises 0.05%-5% of a preservative, 0.5%-10% of a scale inhibitor, 0.1%-5% of a surfactant and a pH regulator; the pH value of the drug detection and collection reagent in the environment is 6.5-8.5; the detection and collection reagent for the drugs in the environment is wide in application range, and can be suitable for rapid collection and detection of the drugs such as morphine, methamphetamine, ketamine, cocaine, cannabis sativa, ecaloin, etomidate and dextromethorphan. The drug detection and collection reagent can effectively reduce the detection threshold value of a high-sensitivity detection plate, further improves the sensitivity of drug detection and analysis, and is suitable for further popularization and application.

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

The present invention relates to a morphinan-type compound, a preparation method therefor, a composition thereof and the use thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan-type compound of the present invention has one or more of the following effect advantages: (1) a relatively high binding affinity for an opioid receptor; (2) a significant agonistic effect on KOR and MOR; (3) good selectivity for a κ receptor; and (4) a good therapeutic effect on inflammatory pain (for example, rapid onset of action or significant analgesic effect).

The present invention discloses a method for dual-ratio fluorescence detection of morphine in blood using nitrogen-doped carbon quantum dots; the present invention uses m-phenylenediamine and spermidine as carbon and nitrogen sources, and synthesizes nitrogen-doped fluorescent carbon quantum dots with high fluorescence quantum yield by microwave method; due to the fluorescence resonance energy transfer effect between morphine and carbon quantum dots, in the presence of morphine, the fluorescence of carbon quantum dots decreases at 350 nm, while increases sharply at 456 nm, and the ratio of the fluorescence intensity at 350 nm to that at 456 nm has a certain linear relationship with the morphine concentration, based on which a fluorescence spectrophotometry for detecting morphine in blood is established; the nitrogen-doped fluorescent carbon quantum dots prepared by the present invention have significant fluorescence sensitization and quenching effects on morphine, and have strong selectivity, and are used for the fluorescence determination of morphine in blood, with the characteristics of high sensitivity and specificity.

This disclosure relates to morphinan compounds and derivatives thereof, pharmaceutically acceptable salts, solvates and hydrates thereof, and compositions comprising the compounds, and use of such compounds and compositions in methods of treating diseases and conditions.

1. Name of the Design Product: Marking Plate (Morphine Tablet and Injection Dosage). 2. Use of the Design Product: For converting the rescue dosage of morphine tablets / injections corresponding to breakthrough pain. 3. Design Key Points of the Design Product: Lies in the shape. 4. Picture or Photograph Most Indicating the Design Key Points: Perspective View.

The invention discloses a method for measuring morphine content in a cough-relieving and phlegm-reducing pill, and aims to improve the quality standard of the cough-relieving and phlegm-reducing pill and guarantee the medication safety of a patient. The method adopts a high performance liquid chromatography and comprises the following steps: precisely weighing a cough-relieving and phlegm-reducing pill sample, grinding, and carrying out ultrasonic extraction by taking 20% methanol containing 5% glacial acetic acid as an extraction solvent to prepare a test solution; preparing a morphine reference substance solution; according to the method, octadecylsilane chemically bonded silica is taken as a filling agent, acetonitrile and a specific mixed solution are taken as a mobile phase for gradient elution, and determination is carried out under the conditions that the column temperature is 30 DEG C and the detection wavelength is 210 nm. The method is verified by specificity, accuracy, repeatability and the like, the result is reliable, the linear relation is good, a low-toxicity organic reagent is used, the method is environment-friendly, the method can be used as a quality control means of Chinese patent medicines containing poppy shells, and the blank of morphine content determination in the existing standard is filled.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The invention belongs to the technical field of medicine, and particularly discloses a preparation method and application of anacycline alkali C and D. The preparation method comprises the following steps: extracting anacycline root medicinal materials by using a mixed solution of acetone and methanol, dissolving by using a hydrochloric acid solution, extracting by using ethyl acetate, adding a saturated sodium bicarbonate solution into an ice-water bath to adjust the pH value, filtering, washing, and drying to obtain the anacycline alkali C and the anacycline alkali D. The preparation method comprises the following steps: extracting the anacycline alkali C and the anacycline alkali D; an alkalized solution is obtained; fully extracting with ethyl acetate and n-butyl alcohol in sequence to obtain crude alkaloid; performing multi-step separation and purification through silica gel column chromatography, MCI gel, Sephadex LH-20 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and the like, and finally performing forward HPLC chiral resolution to obtain a target compound. Activity research shows that the anacycline C and the anacycline D have a remarkable inhibiting effect on mouse writhing reaction caused by acetic acid under the dosage of 5mg / kg, and the analgesic effect of the anacycline C under the dosage of 1mg / kg and 0.2 mg / kg is superior to that of morphine, so that the anacycline C and the anacycline D can be used as novel analgesic lead compounds with development potential.

The invention belongs to the field of medicines, and discloses pyrimido imidazolone derivatives as well as a preparation method and medical application thereof. The pyrimidino imidazolone derivative has a structure as shown in a general formula I. The preparation method comprises the following steps: carrying out substitution reaction on 1-(4-methoxyphenyl)-1-R2-methylamine and a compound 1 under the catalysis of an organic base to obtain a compound 2; carrying out Dieckmann condensation reaction on the compound 2 and excessive CDI to obtain a compound 3; and carrying out Suzuki coupling reaction on the compound 3 and different substituted arylboronic acid or morpholine under the catalysis of sodium carbonate, Pd (OAc) 2 and TPPTS to obtain the pyrimido imidazolone derivative. The pyrimido imidazolone derivative selectively has a strong inhibition effect on proliferation of tumor cells of lung cancer, prostatic cancer, colon cancer, breast cancer, liver cancer and the like, and can be applied to preparation of medicines for treating and / or preventing malignant tumors.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

A system and methods for medication management and incentivized compliance using a distributed ledger are disclosed. A medication dispenser with a lock, weight sensor, and control unit communicates with a blockchain network executing smart contracts that authorize dispensing events, record authenticated telemetry, and account for tokenized dose entitlements normalized in morphine-milligram equivalents (MME). A prescriber device assigns entitlements to a patient wallet; the dispenser unlocks only upon receipt of an on-chain authorization event that cryptographically binds the requested dose to measured inventory and policy constraints. Post-dispense, signed weight deltas are committed to an authenticated store for audit. Optional risk scoring derived from historical usage features gates dispensing or escalates to multi-party authorization. Unused entitlements may be reconciled under policy via redemption logic. The architecture reduces diversion by coupling cryptographic authorization with tamper-evident telemetry and immutable audit trails.

1. Name of the designed product: MORPHX. 2. Use of the designed product: used as a lying bed in furniture. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

The present invention belongs to the medical field, and specifically is a wearable self-injection medical box, comprising a shell; elastic bands are fixedly connected to both sides of the shell; Velcro is fixedly connected to the surfaces of the two elastic bands, and the Velcros are adapted to each other; a through hole is opened on the top surface of the shell; an injection assembly is installed in the through hole; a rubber plug is fixedly connected to the inner wall of the through hole. Accidents are very likely to occur in high-incidence areas such as battlefields or outdoor extreme sports. When an accident occurs, an embodiment of the present invention can be used. When the user is performing extreme sports or entering a high-risk war zone, the elastic band can be first tied to the user's arm through the Velcro. When the user has an accident, the injection assembly can be used to inject sedative solutions such as morphine into the subcutaneous tissue to relieve the user's pain, thereby increasing the probability that the user can persist until rescue arrives, thereby increasing the user's probability of survival.

The invention relates to the technical field of drug concentration monitoring, and particularly discloses a detection kit and a detection method for the drug concentration of anesthetic in blood. The invention discloses a kit for detecting the concentration of narcotics in blood, which is characterized by specifically comprising the following components: a paper cannula spray kit, 0.3-2.0 mg / mL dansyl chloride acetone solution, water, an isotope internal standard acetone solution and an extracting agent, the anesthetic medicine is selected from propofol, cyclopofol and morphine. The detection kit and the detection method for the concentration of the anesthetic in the blood have the advantages of being easy to operate, capable of achieving detection at any time and rapid, detection can be completed within 5 min, the detection accuracy and precision are high, and the concentration of the anesthetic in the blood can be monitored in real time.

The invention discloses a multi-mode fluorescence detection method and a kit for detecting morphine. According to the invention, a fluorescence-ultraviolet multi-mode detection mode is used, and a good visualization effect is achieved. Meanwhile, the detection method is convenient to operate and high in detection efficiency, has good detection sensitivity and linear range, and can be used for sensitive detection of morphine in human serum or other environments. The work provides a new thought for trace drug detection and research of a multi-mode fluorescence sensing system, and has wide application potential in the fields of biomedical detection and public safety maintenance.

The invention relates to a preparation method and application of a compound anacycline B. The compound is prepared by the following steps: crushing an anacycline root medicinal material, soaking in a mixed solvent of acetone and methanol, repeatedly extracting, combining extracting solutions, recovering the solvent to obtain a total extract, dissolving with a hydrochloric acid solution, extracting with ethyl acetate, adding a saturated sodium bicarbonate aqueous solution in an ice-water bath to adjust the pH value, filtering, and drying to obtain the anacycline B; the preparation method comprises the following steps: adding an alkali solution into an alkali solution, respectively extracting with ethyl acetate and n-butyl alcohol to obtain crude alkaloid, carrying out silica gel column chromatography, reversed-phase MCI gel normal-pressure column chromatography, Sephadex LH-20 column chromatography, normal-pressure normal-phase silica gel column chromatography or reversed-phase C-18 column chromatography, carrying out semi-preparative HPLC (High Performance Liquid Chromatography) separation, and carrying out normal-phase HPLC chiral resolution to obtain the compound anacycline B. An analgesic activity test shows that the compound has remarkable analgesic activity on mouse writhing induced by acetic acid under the dosage of 5mg / kg. The morphine derivative has a better analgesic effect than morphine under the dosage of 1mg / kg, can be used as a new drug component or a lead compound of an analgesic, and has a wide development prospect.

The invention provides an application of MCU (Microprogrammed Control Unit) in treating addictive diseases. By means of a conditional knockout dopamine system mouse model, it is observed that motonous nerve excitability caused by heroin, morphine and methamphetamine is remarkably reduced due to deficiency of MCU. In addition, behavioral experiments further prove that the MCU knockout significantly reduces the addiction desire of mice to heroin and methamphetamine. By applying MCU inhibitors, namely mitoxantrone (MTX) and Ru265, the inhibitors are found to be capable of remarkably inhibiting motor nerve excitability caused by heroin and reducing addiction and relapse behaviors of mice on heroin. Mechanism research reveals that MCU knockout inhibits dopamine release caused by opioids and methamphetamine in a nucleus septum (NAc) area, and it is indicated that MCU may serve as an effective target for treating addiction of multiple drugs. The invention provides a brand-new treatment strategy for inhibiting MCU as a clinical treatment for opioid (morphine) or drug (heroin) and methamphetamine addiction for the first time.

Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. In some embodiments A1 is L-Tyr; A2 is a D-Lys, D-Orn, D-Dab, or D-Dpr; A3 is L-Trp; A4 is L-Phe, A5 is an amino acid residue selected from the group consisting of Asp, Glu, iso-Asp, and iso-Glu; A6 is (a) a hydroxy-substituted amino acid residue (HO-AA), or (b) an oligopeptide comprising 2 to 5 amino acid residues comprising the HO-AA; Carb is a carbohydrate group bonded to the sidechain oxygen of the HO-AA by a β3-D-glycosidic bond, and the C-terminus of A6 optionally is amidated, e.g., as a primary amide.

The invention belongs to the technical field of adsorption materials, and particularly relates to a nano magnetic adsorption material as well as a preparation method and application thereof. The nano magnetic adsorption material comprises biochar, nano magnetic particles and hydroxyl, the nano magnetic adsorption material is of a nano cluster structure, and the nano magnetic particles are loaded on the biochar and connected with the hydroxyl; wherein the biochar is prepared from shrimp shells. The nanometer magnetic adsorption material can effectively adsorb psychoactive substances, and especially the adsorption efficiency of morphine can reach 98%.

Provided herein are apomorphine compositions comprising an excipient particle and apomorphine nanoparticles, wherein the surface of the excipient particle is coated by Vapor-phase-deposition with the apomorphine nanoparticles. Also provided herein are methods of their preparation and use for treating, preventing, or ameliorating one or more symptoms of a neurological disorder.